ScreenerHero
VRCIVerici Dx plc
LSE · GB · Healthcare · Diagnostics & Research · vericidx.com
0.2250GBP0.00%Mkt Cap: 6.60M $P/E: —

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transp…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1

Key Statistics

Company
Market Cap6.60M $
Enterprise Value332.37K $
Revenue (TTM)4.70M $
Gross Profit3.64M $
Net Income (TTM)-8.89M $
Revenue/Share0.0064 USD
Last Price0.2250 GBP
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees18
CountryGB
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.04
EV/Revenue0.07
P/S1.40
P/B0.30
EPS (TTM)-0.01
EPS (Forward)0.00
52W Range
0.20003% of range0.9940
52W High0.9940 GBP
52W Low0.2000 GBP
Profitability
Gross Margin77.46%
Oper. Margin-221.13%
EBITDA Margin-174.78%
Profit Margin-189.22%
ROE-106.58%
ROA-87.32%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.60M $
CapEx (TTM)242.41K $
FCF Margin-159.53%
FCF Yield-113.58%
Net Debt-4.04M $
Net Debt/EBITDA0.49
Balance Sheet
Debt/Equity0.03
Current Ratio3.94
Quick Ratio3.61
Book Value/Sh0.0076 GBP
Cash/Share0.0020 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.900 GBP
Upside (mean)+1188.9%
Target Range2.900 GBP – 2.900 GBP
# Analysts1
Ownership
Shares Out.2.29B
Float1.23B
Insiders1.33%
Institutions80.41%
Technical
SMA 500.3259 (-31.0%)
SMA 2000.5434 (-58.6%)
Beta1.22
S&P 52W Chg18.16%
Avg Vol (30d)1.44M
Avg Vol (10d)1.23M
Technical Indicators
RSI (14)21.8
MACD-0.0333
MACD Signal-0.0337
MACD Hist.+0.0004
BB Upper0.3832 GBP
BB Middle0.2700 GBP
BB Lower0.1567 GBP
BB Width83.88%
ATR (14)0.0703 GBP
Vol Ratio (20d)0.36x